AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B
Bio Pharma Dive
DECEMBER 12, 2023
The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Bio Pharma Dive
DECEMBER 12, 2023
The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.
Bio Pharma Dive
JANUARY 5, 2022
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 1, 2024
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)
BioSpace
SEPTEMBER 26, 2023
The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.
BioSpace
APRIL 18, 2024
French healthcare and pharma company Sanofi will terminate an undisclosed number of positions in its U.S. vaccines commercial unit in an effort to streamline the strategic sales structure.
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. So far the winners are Pfizer and Moderna.
XTalks
MAY 29, 2024
The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.
World of DTC Marketing
JULY 28, 2020
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. Moderna, a 10-year-old vaccine developer based in Cambridge, Mass.,
Bio Pharma Dive
SEPTEMBER 2, 2021
The pharma company is in a tight race with rivals, including GSK, to become the first with an approved shot for the infectious disease.
BioSpace
OCTOBER 28, 2020
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
World of DTC Marketing
JULY 22, 2020
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?” health officials agreed to pay $1.95
Medical Xpress
MARCH 13, 2023
Six mobile vaccine production units by German pharma company BioNTech arrived in Rwanda on Monday, the first such shipments to Africa as the continent seeks to boost mRNA vaccine manufacturing.
BioPharma Reporter
NOVEMBER 18, 2020
While governments are now getting ready to ensure large-scale, equitable access and distribution of a COVID-19 vaccine, concern about vaccine hesitancy is growing worldwide. The COVID-19 pandemic is expected to continue to impose enormous burdens on societies and economies globally.
World of DTC Marketing
FEBRUARY 28, 2021
SUMMARY: Pharma companies, like J&J, have received criticism for engaging in illegal activities, such as providing kickbacks and bribes, knowingly shipping adulterated or contaminated drugs to pharmacies, and marketing drugs for unapproved uses. Can a COVID-19 vaccine approval suddenly erase that? billion in penalties.
World of DTC Marketing
AUGUST 3, 2020
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. Personally I would want to know as much as I can before I ask for the vaccine but I also know that greed can make people do stupid things and there is a lot of money at stake here.
BioPharma Reporter
FEBRUARY 2, 2021
Rows about vaccine supply and threats of export blocks donât do anything to bring us closer to ending the COVID-19 pandemic, say campaigners pushing for vaccine equity on a global level.
BioPharma Reporter
MARCH 23, 2021
The pharma company and the CDC are recommending that adults continue routine vaccination during the COVID-19 pandemic to reduce future vaccine-preventable disease (VPD) outbreaks and overall strain on the healthcare system.
Drug Discovery World
DECEMBER 7, 2022
We are excited to open up the waitlist for the next stage, and encourage people from other backgrounds to get involved, including our tech company members.” . The programme is like a vaccine – we expose leaders to trial situations to understand the root causes of how inequality manifests in the workplace and to uncover unconscious biases.
Pharmaceutical Technology
NOVEMBER 15, 2022
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. This also has clear advantages in healthcare settings, particularly when it comes to vaccines. In general, a prefilled syringe is clearly preferred for vaccines.”. A new challenge .
pharmaphorum
APRIL 19, 2021
The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . It is really important and we have seen a lot of pharma companies interested in the UK. Speed is everything in clinical development.
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.
Pharmaceutical Commerce
JULY 7, 2023
Pharma company will produce seven vaccines, as nation aims to strengthen status as a life sciences hub.
pharmaphorum
NOVEMBER 29, 2021
The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – is rumoured to be up for sale. It was billed at the time as a key tool to accelerate the development of new and innovative vaccines to combat some of the world’s most prevalent diseases, from discovery to licensed product.
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
pharmaphorum
DECEMBER 10, 2020
The European Medicines Agency (EMA) says it suffered a cyberattack, with documents relating to a Pfizer and BioNTech’s COVID-19 vaccine accessed. Shortly after however BioNTech confirmed that documents submitted as part of its marketing application for coronavirus vaccine BNT-162b had been accessed by the hackers.
pharmaphorum
OCTOBER 7, 2021
Moderna has said it plans to invest $500 million in a new facility for manufacturing mRNA vaccines in Africa, and has kicked off a search to find a suitable country and location. of Africans have been fully vaccinated against COVID-19, and just 15 African nations have met the agency’s objective of 10% coverage.
pharmaphorum
MARCH 24, 2021
The Prime Minister reportedly told Conservative backbench MPs on a Zoom call that “capitalism” and “greed” was behind the success of the UK’s COVID-19 vaccination programme, before backtracking after realising he had made a blunder and telling attendees to forget the comments. " But he’s wrong.
pharmaphorum
AUGUST 23, 2021
The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
BioPharma Reporter
JANUARY 28, 2022
Contract development and manufacturing organization (CDMO), Recipharm, says it has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.
pharmaphorum
DECEMBER 16, 2022
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
World of DTC Marketing
NOVEMBER 27, 2020
SUMMARY: Business by press release has made pharma executives a lot of money but we still haven’t seen any over reviewed data on COVID 19 vaccines. The American Nurses Association, a national professional organization, said one-third of its members do not intend to take the vaccine, and an additional third are undecided.
BioPharma Reporter
JANUARY 12, 2021
The European Commission had held discussions with French pharma company, Valneva, with a view to securing up to 60 million doses of its inactivated virus COVID-19 vaccine, VLA2001.
Pharmaceutical Technology
JANUARY 16, 2023
Recent cases in the pharmaceutical sector include Poolbeg Pharma finding more than one respiratory syncytial virus (RSV) vaccine candidate with AI by going through a vast amount of early stage clinical data to prioritise candidates and reposition them as novel treatments for RSV infection.
BioPharma Reporter
JUNE 20, 2022
Following the adoption of a critical list of COVID-19 vaccines and treatments, European Union member states and pharma companies will communicate to ensure sufficient supply to meet evolving demand.
The Pharma Data
OCTOBER 21, 2020
More than two dozen researchers and experts have penned a letter to HHS Secretary Alex Azar, National Institutes of Health (NIH) officials and pharma company executives, imploring them to shed more light on the clinical trial designs for federally funded COVID-19 vaccine studies. Source link.
pharmaphorum
FEBRUARY 24, 2021
The FDA has issued guidelines allowing for faster development of updated coronavirus vaccines, based on previously approved shots that have been tweaked to combat emerging variants of the SARS-CoV-2 virus. If vaccines need updating, the FDA expects that manufacturing information will remain generally the same.
pharmaphorum
FEBRUARY 14, 2022
Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and GlaxoSmithKline’s market-leading Shingrix. The biotech has been looking for a development partner for the shot as a chickenpox vaccine.
World of DTC Marketing
SEPTEMBER 23, 2021
SUMMARY: Pfizer will earn over 26 billion dollars from their COVID vaccine, while Moderna and J&J also look to their vaccines for more profit dollars. Here is his rationale: “ When we asked the Pfizer colleagues to develop a Covid-19 vaccine in l ess than a year, you did. trillion social spending package.
pharmaphorum
MARCH 2, 2022
Pfizer’s vaccine for Clostridium difficile (C. The pharma company was quick to point out however that the CLOVER trial of PF-06425090 was undermined by a lower-than expected rate of C. With no approved vaccines to date, C. As it stands, PF-06425090 is still leading the field among candidate vaccines for C.
World of DTC Marketing
APRIL 20, 2021
With medical visits picking up again among patients vaccinated against covid-19, health providers are starting to see the consequences of a year of pandemic-delayed preventive and emergency care as they find more advanced cancer and rotting and damaged teeth, among other ailments. Pfizer could sell $24 billion in Covid Vaccine this year.
pharmaphorum
MARCH 18, 2021
The World Health Organization has backed the safety of the Oxford University/AstraZeneca vaccine ahead of a key announcement from European safety experts later today. Several major European countries including Germany, Italy and France have temporarily suspended use of the vaccine amid fears that it could be linked to blood clots.
pharmaphorum
JULY 15, 2022
In the final piece of a three-part series, Ben Hargreaves explores how manufacturing infrastructure was rapidly built up to the required capacity to ensure sufficient supply of COVID-19 vaccines, and what still remains to be done to improve vaccine equity globally. All angles.
Delveinsight
JULY 29, 2020
Today the whole world is in a search for an effective vaccine candidate against SARS-CoV-2. The vaccine appears to be the only solution to prevent coronavirus. Several pharma and biotech companies are developing and manufacturing safe and effective vaccines to fight coronavirus.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content